BXP.L Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 15:19):

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh...

Stats
Dzisiejszy wolumen	1 080.00
Średni wolumen	46 037.00
Kapitalizacja rynkowa	169.52M
EPS	£2.13 ( 2023-03-31 )
Last Dividend	£3.32 ( 2022-11-17 )
Next Dividend	£0 ( N/A )
P/E	4.22
ATR14	£0 (0.00%)

Beximco Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
POLX.L	0.931
FRP.L	0.923
FWD.L	0.921
KCT.L	0.92
SENS.L	0.917
GRIO.L	0.917
RESI.L	0.915
WNWD.L	0.914
GSF.L	0.913
WATR.L	0.912

10 Najbardziej negatywne korelacje
RR.L	-0.933
REL.L	-0.932
RSVL.L	-0.928
IL0A.L	-0.922
JDW.L	-0.917
FEDF.L	-0.911
XFFE.L	-0.91
MPO.L	-0.91
JREC.L	-0.909
EMRJ.L	-0.906

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Beximco Pharmaceuticals Finanse

Annual	2022
Przychody:	£39.27B
Zysk brutto:	£17.31B (44.09 %)
EPS:	£10.34

FY	2022
Przychody:	£39.27B
Zysk brutto:	£17.31B (44.09 %)
EPS:	£10.34

FY	2022
Przychody:	£34.67B
Zysk brutto:	£15.81B (45.61 %)
EPS:	£11.48

FY	2021
Przychody:	£29.49B
Zysk brutto:	£13.92B (47.21 %)
EPS:	£11.49

Financial Reports:

No articles found.

Beximco Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£3.32 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Beximco Pharmaceuticals Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.98 - Stable (19.61%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£0.174	2008-06-30
Last Dividend	£3.32	2022-11-17
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	£16.75	--
Avg. Dividend % Per Year	1.38%	--
Score	3.34	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.98
Div. Directional Score	8.25	--

Next Divdend (Est)
(2024-05-24)

£0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

3.34

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2008	£0.174	1.17%
2009	£0.405	6.62%
2010	£0	0.00%
2011	£0	0.00%
2012	£0	0.00%
2013	£0	0.00%
2014	£0	0.00%
2015	£1.057	7.02%
2016	£1.730	7.40%
2017	£1.373	2.80%
2018	£1.354	2.48%
2019	£1.605	3.92%
2020	£1.766	4.37%
2021	£3.97	4.14%
2022	£3.32	2.69%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SHG.L	Dividend Knight	2023-11-02	Semi-Annually	4	0.91%
IHP.L	Dividend Knight	2023-06-08	Semi-Annually	7	1.08%
BOCH.L	Dividend Junior	2023-05-04	Insufficient data to determine frequency	2	1.10%
OCN.L	Dividend Knight	2023-05-18	Annually	19	3.96%
ESNT.L	Dividend King	2023-09-21	Semi-Annually	20	4.44%
STAN.L	Dividend Junior	2023-08-10	Annually	32	1.92%
JMAT.L	Dividend Knight	2023-06-08	Semi-Annually	33	1.93%
CAPD.L	Dividend King	2023-08-31	Semi-Annually	10	2.58%
PSHD.L	No Dividend Player	2023-08-17	Annually	6	0.41%
GCP.L	Dividend King	2023-08-10	Quarterly	15	3.86%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.124	1.500	7.53	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0759	1.200	7.47	8.96	[0 - 0.3]
returnOnEquityTTM	0.118	1.500	9.80	10.00	[0.1 - 1]
payoutRatioTTM	0.297	-1.000	7.03	-7.03	[0 - 1]
currentRatioTTM	1.797	0.800	6.02	4.81	[1 - 3]
quickRatioTTM	0.422	0.800	-2.23	-1.781	[0.8 - 2.5]
cashRatioTTM	0.0956	1.500	-0.580	-0.870	[0.2 - 2]
debtRatioTTM	0.106	-1.500	8.24	-10.00	[0 - 0.6]
interestCoverageTTM	9.07	1.000	7.75	7.75	[3 - 30]
operatingCashFlowPerShareTTM	18.77	2.00	3.74	7.49	[0 - 30]
freeCashFlowPerShareTTM	13.77	2.00	3.12	6.24	[0 - 20]
debtEquityRatioTTM	0.160	-1.500	9.36	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.437	1.000	6.06	6.06	[0.2 - 0.8]
operatingProfitMarginTTM	0.186	1.000	8.28	8.28	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.127	1.000	4.85	4.85	[0.2 - 2]
assetTurnoverTTM	0.614	0.800	9.24	7.39	[0.5 - 2]
Total Score				10.52

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.20	1.000	9.68	0	[1 - 100]
returnOnEquityTTM	0.118	2.50	9.87	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	13.77	2.00	5.41	6.24	[0 - 30]
dividendYielPercentageTTM	0.0466	1.500	8.83	0	[0 - 0.4]
operatingCashFlowPerShareTTM	18.77	2.00	3.74	7.49	[0 - 30]
payoutRatioTTM	0.297	1.500	7.03	-7.03	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.194	1.000	7.64	0	[0.1 - 0.5]
Total Score				5.98

Beximco Pharmaceuticals

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.